Table 4– Safety and tolerability of linezolid in 93 multidrug-resistant tuberculosis cases
VariablesTotalCohort treated with linezolid ≤600 mg·day−1Cohort treated with linezolid >600 mg·day−1p-value
Subjects n5439
Exposure to linezolid days61 (35–117)63.5 (46.0–120.0)52.0 (30.0–100.0)0.12
Interruption of linezolid due to adverse events12/93 (12.9)3/54 (5.6)9/39 (23.1)0.01
Time of occurrence of linezolid-related adverse events days32.0 (21.5–62.5)27.5 (15.5–38.0)53.0 (37.5–83.0)0.005
Reversible adverse events13/19 (68.4)2/6 (33.3)11/13 (84.6)0.03
Anaemia13/56 (23.2)5/24 (20.8)8/32 (25.0)0.72
Leukopenia4/68 (5.9)2/35 (5.7)2/33 (6.1)0.95
Thrombocytopenia4/79 (5.1)1/45 (2.2)3/34 (8.8)0.19
Peripheral neuropthy17/54 (31.5)8/24 (33.3)9/30 (30.0)0.79
Optic neuritis1/79 (1.3)1/44 (2.3)0/35 (0.0)0.37
Gastrointestinal disorders5/38 (13.2)2/12 (16.7)3/26 (11.5)0.66
  • Data are presented as median (interquartile range) or n/N (%), unless otherwise stated.